Karl-Josef Langen

Prof. Karl-Josef Langen

MD PhD
orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2005 in Brain
Verified
Journal Article
Open access
PDF file
DPDirk Pauleit
Dirk Pauleit
FFFrank Floeth
Frank Floeth
KHKurt Hamacher
Kurt Hamacher
MRMarkus J. Riemenschneider
Markus J. Riemenschneider
GRGuido Reifenberger
Guido Reifenberger
KLKarl-Josef Langen
Karl-Josef Langen
MRI is commonly used to determine the location and extent of cerebral gliomas. We investigated whether the diagnostic accuracy of MRI could be improved by the additional use of PET with the amino acid O-(2-[18F]fluoroethyl)-l-tyrosine (FET). In a prospective study, PET with FET and MRI was performed in 31 patients with suspected cerebral gliomas. PET and MRIs were co-registered and 52 neuronavigated tissue biopsies were taken from lesions with both abnormal MRI signal and increased FET uptake (match), as well as from areas with abnormal MR signal but normal FET uptake or vice versa (mismatch). Biopsy sites were labelled by intracerebral titanium pellets. The diagnostic performance for the identification of cellular tumour tissue was analysed for either MRI alone or MRI combined with FET PET using alternative free response receiver operating characteristic curves (ROCs). Histologically, 26 biopsy samples corresponded to cellular glioma tissue and 26 to peritumoral brain tissue. The diagnostic performance, as determined by the area under the ROC curve (Az), was Az = 0.80 for MRI alone and Az = 0.98 for the combined MRI and FET PET approach (P < 0.001). MRI yielded a sensitivity of 96% for the detection of tumour tissue but a specificity of only 53%, and combined use of MRI and FET PET yielded a sensitivity of 93% and a specificity of 94%. Combined use of MRI and FET PET in patients with cerebral gliomas significantly improves the identification of cellular glioma tissue and allows definite histological tumour diagnosis. Thus, our findings may have considerable impact on target selection for diagnostic biopsies as well as therapy planning.

5 December 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
ILIan Law
Ian Law
NANathalie L. Albert
Nathalie L. Albert
Javier ArbizuJavier Arbizu
Javier Arbizu
RBRonald Boellaard
Ronald Boellaard
ADAlexander Drzezga
Alexander Drzezga
MWMichael Weller
Michael Weller
These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374–80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199–208, 2016). The information provided should be taken in the context of local conditions and regulations.

7 April 2017 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
KLKarl-Josef Langen
Karl-Josef Langen
NGNorbert Galldiks
Norbert Galldiks
EHElke Hattingen
Elke Hattingen
NSN. Jon Shah
N. Jon Shah

1 April 2006 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
KLKarl-Josef Langen
Karl-Josef Langen
KHKurt Hamacher
Kurt Hamacher
MWMatthias Weckesser
Matthias Weckesser
FFFrank Floeth
Frank Floeth
GSGabriele Stoffels
Gabriele Stoffels
DPDirk Pauleit
Dirk Pauleit

1 February 1992 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
ALA. C. Ludolph
A. C. Ludolph
KLKarl-Josef Langen
Karl-Josef Langen
MRM. Regard
M. Regard
HHH. Herzog
H. Herzog
BKB. Kemper
B. Kemper
LFL. Feinendegen
L. Feinendegen
In this study the regional cerebral glucose utilization and the neuropsychological performance of patients with amyotrophic lateral sclerosis (ALS) was investigated. Special attention was given to neuropsychological tests thought to mirror frontal lobe dysfunction. The regional cerebral glucose utilization was studied in 18 patients using high-resolution positron emission tomography. Clinically all patients displayed upper and lower motor neurone signs. In ALS patients glucose metabolism was significantly reduced in the frontal and in the entire cortex compared with controls; no changes were seen in the cerebellum. Comprehensive neuropsychological assessment of ALS patients compared to a pair matched control group revealed mild frontal dysfunction which in part significantly correlated with reduced glucose metabolism in the cortex and subcortical structures. We conclude that in patients with ALS, glucose consumption is decreased in parts of the brain other than the motor cortex accompanied by mild neuropsychological deficits based on the tests employed in this study.

20 November 2014 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
NGNorbert Galldiks
Norbert Galldiks
VDVeronika Dunkl
Veronika Dunkl
GSGabriele Stoffels
Gabriele Stoffels
MHMarkus Hutterer
Markus Hutterer
MRMarion Rapp
Marion Rapp
KLKarl-Josef Langen
Karl-Josef Langen